Education
About Us
Working with TipRanks
Follow Us
Revolution Medicines (RVMD)
NASDAQ:RVMD
Earnings Data
Report Date
May 12, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-1.09Last Year’s EPS
-0.7Same Quarter Last Year
Strong Buy
Based on 12 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 26, 2025
|% Change Since: -18.84%
|Next Earnings Date:May 12, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in Revolution Medicines' RAS(ON) inhibitor pipeline and a strong financial position to support future operations. However, increased net losses and operating expenses were noted. The overall sentiment leans positive given the advancements in clinical trials and strategic collaborations.Company Guidance
During the Revolution Medicines Q4 2024 earnings call, significant guidance was provided for the upcoming year. The company reported a strong financial position with $2.3 billion in cash and investments, projecting this to fund operations into the second half of 2027. Key priorities for 2025 include executing pivotal trials for daraxonrasib in metastatic pancreatic cancer and non-small cell lung cancer, with enrollment expected to substantially complete this year for a data readout in 2026. The company plans to initiate a first-line metastatic pancreatic cancer trial with daraxonrasib and chemotherapy and is designing a registrational trial for daraxonrasib in resectable pancreatic cancer as an adjuvant treatment. Additionally, Revolution Medicines aims to generate data to inform development priorities for elironrasib and zoldonrasib, with potential pivotal trials anticipated for 2026. The company expects a GAAP net loss between $840 million and $900 million for 2025, driven by increased expenses from clinical development expansions and commercial preparations.Strong Financial Position
Revolution Medicines ended the fourth quarter of 2024 with $2.3 billion in cash and investments, including $823 million from an equity offering, projecting funding for operations into the second half of 2027.
Advancements in RAS(ON) Inhibitor Pipeline
Significant progress was made with RAS-focused drugs, reporting compelling monotherapy clinical data, especially with daraxonrasib in pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer.
Initiation of Phase III Trials
Commencement of Phase III trials for daraxonrasib in non-small cell lung cancer and PDAC, aiming for substantial enrollment completion in 2025.
Strategic Collaborations
Entered into discovery and clinical collaborations to expand treatment strategies, including a PRMT5 inhibitor with Tango and bispecific antibodies with Aethon Therapeutics.
---
RVMD Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
RVMD Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 26, 2025 | $40.50 | $39.08 | -3.51% |
| Nov 06, 2024 | $59.42 | $59.10 | -0.54% |
| Aug 07, 2024 | $42.27 | $41.98 | -0.69% |
| May 08, 2024 | $38.31 | $37.45 | -2.24% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Revolution Medicines (RVMD) report earnings?
Revolution Medicines (RVMD) is schdueled to report earning on May 12, 2025, TBA Not Confirmed.
What is Revolution Medicines (RVMD) earnings time?
Revolution Medicines (RVMD) earnings time is at May 12, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is RVMD EPS forecast?
RVMD EPS forecast for the fiscal quarter 2025 (Q1) is -1.09.
---
